A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Hematologic Neoplasms|Ovarian Cancer|HER2-positive Advanced Solid Tumors|Non Small Cell Lung Cancer|Small-cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Cholangiocarcinoma|Cervical Cancer|TNBC - Triple-Negative Breast Cancer
Interventions: BIOLOGICAL: tebotelimab 1 mg|BIOLOGICAL: tebotelimab 3 mg|BIOLOGICAL: tebotelimab 10 mg|BIOLOGICAL: tebotelimab 30 mg|BIOLOGICAL: tebotelimab 120 mg|BIOLOGICAL: tebotelimab 300 mg|BIOLOGICAL: tebotelimab 400 mg|BIOLOGICAL: tebotelimab 600 mg|BIOLOGICAL: tebotelimab 800 mg|BIOLOGICAL: tebotelimab 1200 mg|BIOLOGICAL: margetuximab
Sponsor: MacroGenics